To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Larimar Therapeutics reports ...
JonesResearch analyst Catherine Novack reiterates a Buy rating on Larimar Therapeutics (LRMR) with a $14 price target after the company reported initial data from a Phase 2 study for nomlabofusp in ...
BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
As of June 30, 2025, the Company had cash, cash equivalents and marketable securities totaling $138.5 million. Together with net proceeds of approximately $65.1 million from the July 2025 public ...
The last time I wrote about Larimar Therapeutics, Inc. (NASDAQ:LRMR) it was in a Seeking Alpha article entitled "Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed ...
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Larimar Therapeutics ( (LRMR)) has issued ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Larimar Therapeutics ( (LRMR)) has issued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback